Torenzo®, an innovative therapeutic solution, has been manufactured and launched for the very first time in Iran by Dr. Abidi Pharmaceuticals, bringing new hope to patients battling Multiple Sclerosis (MS)1 and Ulcerative Colitis (UC)2. This advanced oral medication decreases the risk of relapse in MS patients by up to 48% and significantly reduces UC symptoms by 60%.

Executive Insight on the New Therapy

Commenting on the launch of Torenzo®, Seyed Amir Razavian, CEO of Dr. Abidi Pharmaceuticals, stated: “This medication, scientifically known as Ozanimod, is a highly effective, safe, and premium-quality oral therapy. Administered just once daily, it successfully lowers the risk of disease relapse in MS patients. Furthermore, Torenzo® facilitates a remarkable improvement in clinical symptoms for individuals suffering from Ulcerative Colitis.”

Mechanism of Action and Clinical Superiority

Both MS and Ulcerative Colitis are classified as inflammatory autoimmune diseases. In these conditions, the body’s immune system erroneously attacks healthy cells, leading to severe damage and inflammation in the Central Nervous System (brain and spinal cord) and the gastrointestinal tract (intestines), respectively.

Torenzo® is prescribed as a first- and second-line treatment for adults with relapsing forms of Multiple Sclerosis (RMS). Notably, compared to older therapies within its class, Torenzo® exhibits a highly specific mechanism of action. This selectivity significantly minimizes the requirement for first-dose cardiac monitoring and lowers the overall risk of adverse side effects.

Transforming Ulcerative Colitis Management

For patients enduring moderately to severely active Ulcerative Colitis, Torenzo® serves as an excellent primary treatment option following conventional therapies such as aminosalicylates, corticosteroids, and thiopurines. By robustly suppressing intestinal inflammation, it accelerates rapid symptom relief. Combining optimal clinical efficacy with the convenience of once-daily oral administration, Torenzo® plays a pivotal role in dramatically enhancing patients’ quality of life.

Global Standards and Local Availability

Ozanimod received official approval from the U.S. Food and Drug Administration (FDA) in 2020. Today, this cutting-edge molecule is being domestically manufactured and supplied for the first time in Iran under the brand name Torenzo® by Dr. Abidi Pharmaceuticals.

Fully approved by the Iran Food and Drug Administration (IFDA), Torenzo® is currently available as a prescription-only (Rx) medication in pharmacies nationwide.

About Dr. Abidi Pharmaceuticals

As the foremost and oldest pharmaceutical company in Iran with a distinguished legacy spanning over  80years, Dr. Abidi Pharmaceuticals is the proud inheritor of quality and innovation within the nation’s pharmaceutical industry. By strictly adhering to rigorous quality control standards and consistently providing highly effective, essential therapeutic solutions to elevate public health, Dr. Abidi Pharmaceuticals has always stood—and will continue to stand—by the side of all Iranians.

1 Multiple Sclerosis

2 Ulcerative Colitis

IR-0726-TRN-2145-PR